Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials Academic Article Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antiretroviral Therapy, Highly Active
  • Burkitt Lymphoma
  • Lymphoma, AIDS-Related

abstract

  • National Cancer Institute of the National Institutes of Health.

publication date

  • April 2017

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S2352-3026(17)30028-5

PubMed ID

  • 28314699

Additional Document Info

start page

  • e176

end page

  • e182

volume

  • 4

number

  • 4